The purpose of this study is to evaluate the efficacy and safety of \*\*Disitamab Vedotin combined with Tislelizumab and CAPOX versus Tislelizumab combined with CAPOX\*\* as first-line treatment for patients with HER2-low advanced gastric or gastroesophageal junction adenocarcinoma.
Voluntarily consent to participate in the study and sign the informed consent form
Expected survival period >12 weeks
ECOG Performance Status 0 or 1
Histologically confirmed unresectable locally advanced, metastatic, or recurrent gastric or gastroesophageal junction adenocarcinoma
Presence of central nervous system (CNS) metastasis and/or carcinomatous meningitis
Peripheral neuropathy > Grade 1
Tumor lesions with a tendency to bleed
Uncontrolled diarrhea